Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

Racial disparities in lung transplantation rates in CF suggest that HEMT has benefitted White patients more than Black and Hispanic patients.

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase, the aim ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...

It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...

Boehringer Ingelheim and partners have commenced the Phase I/II LENTICLAIR 1 trial of gene therapy BI 3720931 targeting ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...